Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
31,523,534
-
Total 13F shares
-
4,000,486
-
Share change
-
+69,139
-
Total reported value
-
$4,229,364
-
Price per share
-
$1.06
-
Number of holders
-
24
-
Value change
-
+$106,912
-
Number of buys
-
12
-
Number of sells
-
10
Institutional Holders of ImmunoPrecise Antibodies Ltd. - Common Shares, no par value (IPA) as of Q2 2025
As of 30 Jun 2025,
ImmunoPrecise Antibodies Ltd. - Common Shares, no par value (IPA) was held by
24 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
4,000,486 shares.
The largest 10 holders included
INGALLS & SNYDER LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, XTX Topco Ltd, TWO SIGMA INVESTMENTS, LP, CIBC WORLD MARKET INC., RENAISSANCE TECHNOLOGIES LLC, Virtu Financial LLC, Federation des caisses Desjardins du Quebec, Baader Bank Aktiengesellschaft, and Gradient Capital Advisors, LLC.
This page lists
24
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.